Inventor · disambiguated record
Peng Li
Also filed as: LI PENG · LI PENG-HUI
208 granted patents·109 pending applications·3,237 citations·filing 2004–2025
99Inventor score
Files withINTRA CELLULAR THERAPIES INC156LI PENG34RHODIA OPERATIONS8GUANGDONG RAYNOVENT BIOTECH CO LTD6MEDSHINE DISCOVERY INC6
Top patents by PatentIndex Score
317 records- 0199USD1085800SElectric heating plateLI PENG·Filed 2025·Granted Jul 29, 2025·6 cites·1 claims
- 0299US11407751B2Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalineINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Aug 9, 2022·19 cites·1 claims
- 0399US11331316B2Amorphous solid dispersionsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted May 17, 2022·27 cites·20 claims
- 0499US9371324B2Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disordersINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Jun 21, 2016·90 cites·26 claims
- 0598US12128043B2Pharmaceutical capsules comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2024·Granted Oct 29, 2024·10 cites·29 claims
- 0698US12070459B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2023·Granted Aug 27, 2024·16 cites·28 claims
- 0798US11844757B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Dec 19, 2023·10 cites·14 claims
- 0898US11806347B2Transmucosal methods for treating psychiatric and neurological conditionsINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Nov 7, 2023·20 cites·58 claims
- 0998US11806348B2Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2022·Granted Nov 7, 2023·18 cites·23 claims
- 1098US11773095B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2022·Granted Oct 3, 2023·9 cites·21 claims
- 1198US11753419B24-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disordersINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Sep 12, 2023·6 cites·26 claims
- 1298US11723909B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Aug 15, 2023·18 cites·34 claims
- 1398US11690842B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2021·Granted Jul 4, 2023·11 cites·20 claims
- 1498US11680065B2Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous systemINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jun 20, 2023·17 cites·19 claims
- 1598US11560382B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jan 24, 2023·17 cites·25 claims
- 1698US11453670B2Substituted heterocycle fused gamma-carbolines synthesisINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Sep 27, 2022·15 cites·28 claims
- 1798US11427587B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Aug 30, 2022·31 cites·13 claims
- 1898US11311536B2Amorphous solid dispersionsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Apr 26, 2022·25 cites·17 claims
- 1998US11096944B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Aug 24, 2021·28 cites·28 claims
- 2098US11052084B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jul 6, 2021·18 cites·18 claims
- 2198US11052083B2Transmucosal methods for treating psychiatric and neurological conditionsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jul 6, 2021·27 cites·26 claims
- 2298US11026951B2Methods of treating bipolar disorderINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Jun 8, 2021·38 cites·24 claims
- 2398US10960010B2Pharmaceutical compositions for sustained or delayed releaseINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Mar 30, 2021·38 cites·24 claims
- 2498US10960009B2Methods of treating schizophrenia and depressionINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Mar 30, 2021·39 cites·19 claims
- 2598US10899762B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2020·Granted Jan 26, 2021·29 cites·21 claims
- 2698US10844061B2Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous systemINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Nov 24, 2020·33 cites·17 claims
- 2798US10799500B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Oct 13, 2020·28 cites·17 claims
- 2898US10688097B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Jun 23, 2020·48 cites·23 claims
- 2998US10597394B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Mar 24, 2020·30 cites·13 claims
- 3098US10472359B2Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl) butan-1-one for inhibiting serotonin reuptake transporter activityINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Nov 12, 2019·35 cites·20 claims
- 3198US10464938B2Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereofINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Nov 5, 2019·33 cites·12 claims
- 3298US10322134B2MethodsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Jun 18, 2019·49 cites·20 claims
- 3398US10245260B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Apr 2, 2019·38 cites·15 claims
- 3498US10077267B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Sep 18, 2018·69 cites·18 claims
- 3598US10072010B2Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activityINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Sep 11, 2018·53 cites·16 claims
- 3698US9956227B2Method for the treatment of residual symptoms of schizophreniaINTRA CELLULAR THERAPIES INC·Filed 2014·Granted May 1, 2018·78 cites·25 claims
- 3798US9751883B2Preparation of certain [((6BR,10AS)-2,3,6B,7,8,9,10, 10A-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereofINTRA CELLULAR THERAPIES INC·Filed 2016·Granted Sep 5, 2017·86 cites·28 claims
- 3898US9745300B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2015·Granted Aug 29, 2017·82 cites·40 claims
- 3998US9708322B2Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activityINTRA CELLULAR THERAPIES INC·Filed 2014·Granted Jul 18, 2017·93 cites·7 claims
- 4098US9428506B2Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disordersINTRA CELLULAR THERAPIES INC·Filed 2013·Granted Aug 30, 2016·82 cites·30 claims
- 4198US9315504B2Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereofINTRA CELLULAR THERAPIES INC·Filed 2014·Granted Apr 19, 2016·88 cites·5 claims
- 4298US8664207B2Organic compoundsLI PENG·Filed 2009·Granted Mar 4, 2014·99 cites·31 claims
- 4398US8273751B2Organic compoundsLI PENG·Filed 2008·Granted Sep 25, 2012·59 cites·3 claims
- 4497US12122792B2Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disordersINTRA CELLULAR THERAPIES INC·Filed 2023·Granted Oct 22, 2024·3 cites·35 claims
- 4597US11376249B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Jul 5, 2022·29 cites·19 claims
- 4697US11066407B2Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereofINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Jul 20, 2021·14 cites·10 claims
- 4797US11014925B2Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamideINTRA CELLULAR THERAPIES INC·Filed 2017·Granted May 25, 2021·26 cites·20 claims
- 4897US10906906B2Organic compoundsINTRA CELLULAR THERAPIES INC·Filed 2017·Granted Feb 2, 2021·23 cites·18 claims
- 4997US10716786B2Transmucosal and subcutaneous compositionsINTRA CELLULAR THERAPIES INC·Filed 2018·Granted Jul 21, 2020·38 cites·24 claims
- 5097US10695345B2Pharmaceutical capsule compositions comprising lumateperone mono-tosylateINTRA CELLULAR THERAPIES INC·Filed 2019·Granted Jun 30, 2020·21 cites·18 claims
Showing the top 50 of 317 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Peng Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →